



## BioLineRx to Report Second Quarter 2015 Results on August 20, 2015

August 13, 2015 11:01 AM IDT

*Management to hold a conference call at 10:00 a.m. EDT*

TEL AVIV, Israel--(BUSINESS WIRE)--Aug. 13, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the quarter ended June 30, 2015 on Thursday, August 20, 2015, before the U.S. markets open.

The Company will host a conference call on Thursday, August 20 at 10:00 a.m. EDT featuring remarks by Kinneret Savitsky, Ph.D., Chief Executive Officer of BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of BioLineRx. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website, [www.biolinerx.com](http://www.biolinerx.com). Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-888-668-9141 from the U.S. or +972-3-918-0610 internationally.

A replay of the conference call will be available approximately two hours after completion of the live conference call at [www.biolinerx.com](http://www.biolinerx.com). A dial-in replay of the call will be available until August 23, 2015; please dial 1-888-782-4291 from the U.S. or +972-3-925-5925 internationally.

### About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML), and has successfully completed a Phase 1 study in stem cell mobilization; BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study; and BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria).

In December 2014, BioLineRx entered into a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept for potential future licensing by Novartis.

For more information on BioLineRx, please visit [www.biolinerx.com](http://www.biolinerx.com) or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20150813005403/en/>

Source: BioLineRx Ltd.

[Tiberend Strategic Advisors, Inc.](http://www.tiberend.com)

Joshua Drumm, Ph.D., +1-212-375-2664

[jdrumm@tiberend.com](mailto:jdrumm@tiberend.com)

or

Andrew Mielach, +1-212-375-2694

[amielach@tiberend.com](mailto:amielach@tiberend.com)

or

BioLineRx Ltd.

Tsipi Haitovsky, +972-3-6240871

Public Relations

[tsipihai5@gmail.com](mailto:tsipihai5@gmail.com)